S.Roehrig,A.Straub,J.Pohlmann,T.Lampe,J.Pernerstorfer,K.-H. Schlemmer , P.,Reinemer and E.,Perzborn,-, 2005.-yl} methyl) thiophene-2- carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor,J. Med 48 3 -
J.Aalbers, 2011.FDA approves rivaroxaban for prevention of deep-vein thrombosis in surgery: drug trends in cardiology,CVJA. 22 -
Fox , J. P.,Piccini , D.,Wojdyla , R. C.,Becker , J. L.,Halperin , C. C.,Nessel , J. F.,Paolini , G. J.,Hankey , K. W.,Mahaffey , M.R.,Patel, 2011.Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment,Eur. Heart. J. 32 2387 -2394
A.Straub,T.Lampe,J.Pohlmann,S.Röhrig,E.Perzborn,Y.Miao,D. M.Sarasohn,R.Parameswaran,S.Stefanik,P.Samedy,J.Wills,S.Harnicar, 2017.Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study,J. Thromb Thrombolysis 43 166 -171
B.Eriksson,L.Borris,O.Dahl,S.Haas,A.Kakkar,L.Kwong,F.Misselwitz,A.Turpie, 2009.-a novel, oral, direct factor xa inhibitor-for prevention of venous thromboembolism after major orthopaedic surgery: overview of three phase ii trials,Orthop. Proc. 91 -
W.Mueck,B. I.Eriksson,K. A.Bauer,L.Borris,O. E.Dahl,M.Gent,S.Haas,M. V.Huisman,A. K.Kakkar, 2008.Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery,Clin. Pharmacokinet 47 -
R.Altman,H. O.Vidal, 2011.Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective, 9 -
R.Goel,K.Srivathsan, 2012.Newer oral anticoagulant agents: a new era in medicine,Curr. Cardiol. Rev. 8 -
M. A.Miyares,K.Davis, 2012.Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient,Am. J. Health Syst. Pharm. 69 -
D.Adcock,R.Gosselin,Y.Tian,X.Lv,X.Xiao,M.Zhan,C.Liao, 2018.The selectivity and bioavailability improvement of novel oral anticoagulants: An overview,Eur. J. Med 146 299 -317
T. A.Fattah,A.Saeed,) D.Kubitza,M.Becka,W.Mueck,M.Zuehlsdorf, 2006.pharmacokinetics of rivaroxaban-an oral, direct factor Xa inhibitor-are not affected by aspirin,J. Clin. Pharmacol 46 981 -990
D.Kubitza,M.Becka,G.Wensing,B.Voith,M.Zuehlsdorf,b) L. Manchikanti , A. D.,Kaye , F. J.,Falco, 2018.Antithrombotic and antiplatelet therapy,In Essentials of Interventional Techniques in Managing Chronic Pain 53 59 -
M. R. Patel , K. W.,Mahaffey , J.,Garg , G.,Pan , D. E.,Singer , W.,Hacke , G. Breithardt, J. L.,Halperin , G. J.,Hankey and J. P.,Piccini,Mavrakanas , C. F.,Samer , S. J.,Nessim , G. Frisch, M. L.,Lipman, 2017.Apixaban pharmacokinetics at steady state in hemodialysis patients,J. Am. Soc. Nephrol., ASN 2016090980 -
C. Negrier , J.,Goudemand , Y.,Sultan , M.,Bertrand , C.,Rothschild and P.,Lauroua, 1997.Factor Eight Bypassing Activity, Thromb, 77 -
M.Crowther,M. A.Crowther, 2015.Antidotes for novel oral anticoagulants, Arterioscler Thromb Vasc Biol, 35 -
S.Heitmeier,V.Laux,A.Buchmüller,Levy , K.,Moore , M.,Neal , D.,Schneider , V.,Marcsisin , J.,Ariyawansa , J.,Weitz, 2018.Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers,J. Thromb. Haemost. 16 54 -64
M.Harwardt, 2007.Recombinant factor VIIa partially reverses the effects of the factor Xa inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors,W640 -
J. Dinkelaar , P.,Molenaar , M.,Ninivaggi , B.,Laat , H.,Brinkman and A.,Leyte,J.Thromb, 2013.In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban, 11 -
M. Levi , K.,Moore , C.,Castillejos , D.,Kubitza , S.,Berkowitz , S.,Goldhaber , M.,Raghoebar , M.,Patel , J.,Weitz and J. Levy, 2014.Comparison of threeand four-factor prothrombin complex concentrates on the anticoagulant effects of rivaroxaban in healthy volunteers,J. Thromb. Haemost. 12 -
E. S.Eerenberg,P. W.Kamphuisen,M. K.Sijpkens,J. C.Meijers,H. R.Buller,M.Levi, 2011.Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate, 124 -
Godier , A.,Miclot , B. Le,Bonniec , M.,Durand , A. M.,Fischer , J.,Emmerich , C.,Marchand-Leroux , T.,Lecompte,C. M. Samama,J. ASA., 2012.Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model, 116 -
F.Dentali,C.Marchesi,M. G.Pierfranceschi,M.Crowther,D.Garcia,E.Hylek,D. M.Witt,N. P.Clark,A.Squizzato,D.Imberti, 2011.Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists, Thromb, 106 -
Romualdi , E.,Rancan , S.,Siragusa and W.,Ageno, 2010.Managing bleeding complications in patients treated with the old and the new anticoagulants,Curr. Pharm. Des. 16 -
R.Marlu,E.Hodaj,A,J. L.Crackowski,G.Pernod, 2012.Effect of nonspecific reversal agents on anticoagulant activity of dabigatran and rivaroxaban, 108 -
J. C.Keenan,C. T.Morton,D. J.Dries, 2014.Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates,BioMed Res. Int. -
K.Devreese,W.Wijns,I.Combes,M. F.Hoylaerts, 2007.Thrombin generation in plasma of healthy adults and children: chromogenic versus fluorogenic thrombogram analysis,Thromb. Haemost. 98 -
M. Ninivaggi , R.,Apitz-Castro , Y.,Dargaud , B. de Laat, H. C.,Hemker and T.,Lindhout, 2012.Wholeblood thrombin generation monitored with a calibrated automated thrombogram-based assay,Clin. Chem 58 -
M. Levi , T.,Moore , C.,Castillejos , S.,Berkowitz , D.,Kubitza , S.,Goldhaber , J.,Weitz and J. Levy,, 2013.Effects of three-factor and four-factor prothrombin complex concentrates on the pharmacodynamics of rivaroxaban, 11 -
N. S.Key,C.Negrier, 2007.Coagulation factor concentrates: past, present, and future, The Lancet, 370 -
Gruber , U. M.,Marzec , U.,Buetehorn , S. R.,Hanson, 2008.Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates,Practice., 2 -
G.Escolar,V.Fernandez-Gallego,J. C.Reverter,V. V.Sanz,P.Molina,I.Lopez-Vilchez,M.Diaz-Ricart,A. M.Galan, 2013.Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood, PloS one, 8 -
Ehrlich , M.,Henzl and E.,Gomperts, 2002.Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse events, 8 -
Gruber , U. Marzec, U.,Buetehorn , S.,Hanson, 2009.Reversal of the antihaemostatic effects of rivaroxaban by activated factor VII and activated prothrombin complex in primates, Haematol, 181 -
W. Zhou , S.,Schwarting , S.,Illanes , A.,Liesz , M.,Middelhoff , M.,Zorn , M.,Bendszus , S.,Heiland , J. Van Ryn,R.Veltkamp, 2011.Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran, 42 -
M. K. Körber , E.,Langer , S.,Ziemer , E.,Perzborn , C.,Gericke and C. v.,Heymann, 2014.Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study,Clin. Appl 20 -
F. R.DeGuzman,S. J.Hollenbach,M. J.Karbarz,K.Abe,G.Lee,P.Luan,A.Hutchaleelaha,M.Inagaki and P. B. Conley, 2013.A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa,Nat. Med 19 -
K.Ghadimi,K. E.Dombrowski,J. H.Levy,I. H.Welsby, 2016.Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation,Expert Rev. Hematol. 9 -
S. J.Hollenbach,S.Tan,G.Lee,H.Athiwat,M.Inagaki,U.Sinha, 2012.PRT064445 but not recombinant Fviia reverses rivaroxaban induced anticoagulation as measured by reduction in blood loss in a rabbit liver laceration model, Blood, 120 -
M. Vandana , K.,Michael , L.,Genmin , P. B.,Conley , H.,Stanley , J.,Castillo , A.,Hutchaleelaha , M.,Karbarz , J. P.,Lin and L.,Barron, 2013.A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxabaninduced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors, 122 -
B.Laulicht,S.Bakhru,C.Lee,C.Baker,X.Jiang,E.Mathiowitz,J.Costin,S.Steiner, 2012.Small molecule antidote for anticoagulants,A11395 126 -
S.Hodin,J.Lanoiselée,J.Escal,S.Accassat,T.Basset,L.Bertoletti,P.Mismetti,X.Delavenne, 2016.,Effect of Activated Charcoal on Rivaroxaban Complex Absorption, Clin. Pharmacokinet 56 -
W.Ageno,A. S.Gallus,A.Wittkowsky,M.Crowther,E. M.Hylek,G.Palareti, 2012.Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines, Chest J, 141 -
A,-C. Martin , B. Le,Bonniec,A.-M. Fischer , C.,Marchand-Leroux , P.,Gaussem,C.-M. Samama , A.,Godier, 2013.Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis,Int. J. Cardiol. 168 -
F. R.DeGuzman,S. J.Hollenbach,D. R.Phillips, 2008.Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors,Am Soc Hematology -
JanssenPharmaceuticals, 2014.Xarelto prescribing information, -
X.Wang,S.Mondal,J.Wang,G.Tirucherai,D.Zhang,R. A.Boyd,C.Frost, 2014.Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects,Am. J. Cardiovasc. Drugs. 14 -
J. D. Douketis , A. C.,Spyropoulos , F. A.,Spencer , M.,Mayr , A. K.,Jaffer , M. H.,Eckman , A. S.,Dunn , R.,Kunz, 2012.Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines,Chest. 141 -
D.Sankyo, 2015.,Daiichi Sankyo -
Lai , N.,Davidson , S.,Galloway , J.,Thachil, 2014.Perioperative management of patients on new oral anticoagulants,Br. J. Surg. 101 -